Complement system in psoriatic arthritis: A useful marker in response prediction and monitoring of anti-TNF treatment

Clinical and Experimental Rheumatology

Volumn 30, Issue 1, 2012, Pages 23-30

  Chimenti, Maria Sole ^a   Perricone, Carlo ^b   Graceffa, Dario ^a   Di Muzio, Gioia ^a   Ballanti, Eleonora ^a   Guarino, Maria Domenica ^a   Conigliaro, Paola ^a   Greco, Elisabetta ^a   Kroegler, Barbara ^a   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti TNF; C3; Complement; Disease activity; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOSPORIN; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG MONITORING; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; C-REACTIVE PROTEIN; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863752634     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. MYERS WA, GOTTLIEB AB, MEASE P: Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24: 438-47.
2. HUEBER AJ, MCINNES IB: Immune regulation in psoriasis and psoriatic arthritis--recent developments. Immunol Lett 2007; 114: 59-65.
3. TURKIEWICZ AM, MORELAND LW: Psoriatic arthritis: current concepts on pathogenesisoriented therapeutic options. Arthritis Rheum 2007; 56: 1051-66.
4. MEE JB, JOHNSON CM, MORAR N et al.: The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 2007; 171: 32-42.
5. SJOBERG AP, TROUW LA, BLOM AM: Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30: 83-90.
6. BRODEUR JP, RUDDY S, SCHWARTZ LB et al.: Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1531-7.
7. LINTON SM, MORGAN BP: Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999; 36: 905-14.
8. MOLLNES TE, PAUS A: Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 1359-64.
9. GORDON KB, LANGLEY RG, LEONARDI C et al.: Clinical response to Adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
10. PAPOUTSAKI M, COSTANZO A, CHIMENTI MS et al.: Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin Biol Ther 2008; 8: 363-70.
11. MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
12. MEASE PJ: Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett 2003; 8: 1-4.
13. ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-36.
14. LUBRANO E, SPADARO A, MARCHESONI A et al.: The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011; 29: 80-4.
15. MEASE PJ, ANTONI CE: Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005; 64 (Suppl. 2): ii78-82.
16. KAYMAKCALAN Z, SAKORAFAS P, BOSE S et al.: Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308-16.
17. HELLIWELL PS, MARCHESONI A, PETERS M et al.: Cytidine deaminase activity, C reactive protein, histidine, and erythrocyte sedimentation rate as measures of disease activity in psoriatic arthritis. Annals of the Rheumatic Diseases 1991; 50: 362-5.
18. TAYLOR W, GLADMAN D, HELLIWELL P et al.: CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
19. FRANSEN J, CREEMERS MC, VAN RIEL PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-5.
20. FINLAY AY, KHAN GK, LUSCOMBE DK et al.: Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. Br J Dermatol 1990; 123: 751-6.
21. HUSTED JA, GLADMAN DD, LONG JA et al.: A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995; 13: 439-43.
22. VAN GESTEL AM, PREVOO ML, VAN'T HOF MA et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
23. AGOSTONI A, AYGÖREN-PÜRSÜN E, BINKLEY KE et al.: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114: S51-131.
24. PERRICONE R, DE CAROLIS C, GIACOMELLO F et al.: Impaired human ovarian follicular fluid complement function in hereditary angioedema. Scand J Immunol 2000; 51: 104-8.
25. PERRICONE R, PASETTO N, DE CAROLIS C et al.: Functionally active complement is present in human ovarian follicular fluid and can be activated by seminal plasma. Clin Exp Immunol 1992; 89: 154-7.
26. ROSENBERG EW, NOAH PW, WYATT RJ et al.: Complement activation in psoriasis. Clin Exp Dermatol 1990; 15: 16-20.
27. PARTSCH G, BAUER K, BRÖLL H et al.: Complement C3 cleavage product in synovial fluids detected by immunofixation. Z Rheumatol 1991; 50: 82-5.
28. FIRESTEIN GS, PAINE MM, LITTMAN BH: Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991; 34: 1094-105.
29. SAMPIETRO T, BIGAZZI F, DAL PINO B et al.: Up regulation of C3, C4, and soluble intercellular adhesion molecule-1 co-expresses with high sensitivity C reactive protein in familial hypoalphalipoproteinaemia: further evidence of inflammatory activation. Heart 2004; 90: 1438-42.
30. SZÉPLAKI G, PROHÁSZKA Z, DUBA J et al.: Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383-9.
31. MOURÃO AF, RUSTIN M, ISENBERG D: Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literature. Clin Exp Rheumatol 2010; 28: 408-10.
32. KRISTENSEN LE, GÜLFE A, SAXNE T et al.: Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008; 67: 364-9.
33. MOLD C, GEWURZ H, DU CLOS TW: Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42: 23-30.
34. MITOMA H, HORIUCHI T, TSUKAMOTO H et al.: Mechanisms for cytotoxic effects of anti tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, Etanercept, and Adalimumab. Arthritis Rheum 2008; 58: 1248-57.
35. MOLENAAR ET, VOSKUYL AE, FAMILIAN A et al.: Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001; 44: 997-1002
36. GLADMAN DD, TOM BD, MEASE PJ et al.: Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010 July 1.
37. CHUNG SJ, KWON YJ, PARK MC et al.: The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 2011; 52: 113-20.
38. GRATACO'S J, CASADO E, REAL J et al.: Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007; 66: 493-7.
39. GLINTBORG B, OSTERGAARD M, DREYER L et al.: Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the Danish nationwide DANBIO registry. Arthritis Rheum 2010 Oct 27.
40. SABER TP, NG C, RENARD G, LYNCH BM et al.: Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: R94.
41. GLINTBORG B, OSTERGAARD M, KROGH NS et al.: Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69: 2002-8.
42. DE VRIES MK, VAN EIJK IC, VAN DER HORSTBRUINSMA IE et al.: Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009; 61: 1484-90.
43. SABER TP, NG CT, RENARD G et al.: Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: R94.